tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Platz KP et al. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. 1994 Transplant. Proc. pmid:7527952
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Tze WJ et al. Prolongation of pig islet xenograft survival in rats by local immunosuppression with FK 506. 1994 Transplant. Proc. pmid:7513471
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Yabuuchi H et al. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. 1991 Transplant. Proc. pmid:1703718
McCauley J et al. The effects of FK 506 on renal function after liver transplantation. 1990 Transplant. Proc. pmid:1689887
Kanter J et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. 2009 Jul-Aug Transplant. Proc. pmid:19715860
Bilbao I et al. Indications and management of everolimus after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715864
TuÄŸcu M et al. Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report. 2015 Transplant. Proc. pmid:26093759
Facundo C et al. Results of a triple induction regime with tacrolimus, mycophenolate mofetil, and prednisone in renal transplantation. 2002 Transplant. Proc. pmid:11959203
García-Meseguer C et al. Efficacy and safety of basiliximab in pediatric renal transplantation. 2002 Transplant. Proc. pmid:11959206
Rafael-Valdivia L et al. How long should initiation of calcineurin inhibitors be delayed to protect renal function in liver transplantation? 2011 Transplant. Proc. pmid:21486577
Charco R et al. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients. 2011 Transplant. Proc. pmid:21486582
McDiarmid S et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636564
Wiesner RH Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. 1998 Transplant. Proc. pmid:9636565
Santos T et al. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients. 2015 Transplant. Proc. pmid:26036483
Luk JM et al. Immunosuppressive effects of Tripterygium wilfordii polysaccharide on LPS-stimulated human monocytes. 2000 Transplant. Proc. pmid:11120045
Higuchi K et al. FK506 induces the atrophy of enteric ganglia in small bowel transplantation, which can be prevented by the neuropeptide bombesin. 2006 Jul-Aug Transplant. Proc. pmid:16908293
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Mayer AD Four-year follow-up of the European Tacrolimus Multicenter Renal Study. 1999 Transplant. Proc. pmid:10576038
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Harrison DM et al. Reduction in hospital stay after liver transplantation. 1996 Transplant. Proc. pmid:8623451
Kaplinsky E et al. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. 2012 Transplant. Proc. pmid:23146455
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Martín-Mateos RM et al. Initial immunosuppression with or without basiliximab: a comparative study. 2012 Transplant. Proc. pmid:23146457
Barten MJ et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. 2005 Transplant. Proc. pmid:16387162
Chueh SC et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. 2004 Transplant. Proc. pmid:15518745
Morimoto T et al. Pancreaticoduodenal allotransplantation with FK 506 in the dog. 1990 Transplant. Proc. pmid:1691550
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Pan F et al. FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. 1994 Transplant. Proc. pmid:7518113
Valdivia LA et al. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. 1994 Transplant. Proc. pmid:7518123
Lischke R et al. Initial single-center experience with sirolimus after lung transplantation. 2006 Transplant. Proc. pmid:17112886
Frank B et al. Neurotoxicity of FK 506 in liver transplant recipients. 1993 Transplant. Proc. pmid:7682355
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Klintmalm GB et al. Rejection: FK 506 for rescue or maintenance. 1993 Transplant. Proc. pmid:7682356
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Matsuura T et al. Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. 1991 Transplant. Proc. pmid:1721316
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Moreno Gonzales M et al. Sublingual Tacrolimus in Liver Transplantation: A Valid Option? Transplant. Proc. pmid:27569953
Wang SS et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. 2008 Transplant. Proc. pmid:18929814
Schumacher G et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. 2002 Transplant. Proc. pmid:12176410
Li J et al. Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. 2008 Transplant. Proc. pmid:18589137
Ennaifer R et al. Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? A case report. 2015 Transplant. Proc. pmid:25891739
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Takaya S et al. Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. 1991 Transplant. Proc. pmid:1721348
Bouchta NB et al. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation. 2005 Transplant. Proc. pmid:15919485
Wasiak D et al. Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report. 2016 Transplant. Proc. pmid:27496507
Cardinal H et al. The evolution of kidney function after lung transplantation: a retrospective cohort study. 2009 Transplant. Proc. pmid:19857746
Numakura K et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. 2005 Transplant. Proc. pmid:15919487
Langrehr JM et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. 2002 Transplant. Proc. pmid:12176487
Varo E et al. Incidence of cytomegalovirus infection and disease in orthotopic liver transplant patients immunosuppressed with cyclosporin versus tacrolimus. 2002 Transplant. Proc. pmid:12176488
De Ruvo N et al. Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182760
Takahashi N et al. Nitric oxide generation in renal allograft recipients. 1998 Transplant. Proc. pmid:9838306
Zucker K et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123027
Sellers M et al. Incidence of late acute rejection and progression to chronic rejection in pediatric liver recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123065
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
Costa A et al. Stimulatory effect of FK506 and erythromycin on pig intestinal motility. 1996 Transplant. Proc. pmid:8907957
Sun CK et al. Intensive care after orthotopic liver transplantation. 1994 Transplant. Proc. pmid:7520627
Sato K et al. Effectiveness of triple regimen immunosuppression in canine pancreatic allotransplantation. 1994 Transplant. Proc. pmid:7520628
Yin DP et al. Efficacy of FK506, leflunomide, anti-CD4, and CTLA4IG treatments in rat to mouse pancreas xenograft transplantation. 2000 Transplant. Proc. pmid:10936320
Prasad SJ et al. In vitro effects of cyclosporine and FK 506 on the renal cortex. 1991 Transplant. Proc. pmid:1721380
Witzigmann H et al. Immunosuppression with sirolimus/tacrolimus combination in pancreas transplantation: 1-year results. 2002 Transplant. Proc. pmid:12493472
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Nanmoku K et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. 2008 Transplant. Proc. pmid:18790241
Citterio F et al. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up. 2002 Transplant. Proc. pmid:12176535
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Hariharan S et al. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123462
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Madariaga JR et al. The long-term efficacy of multivisceral transplantation. 2000 Transplant. Proc. pmid:10995918
Fishbein T et al. Isolated intestinal transplantation in adults with nonreconstructible GI tracts. 2000 Transplant. Proc. pmid:10995925
Tze WJ et al. Long-term survival of islet allografts in diabetic rats treated with FK 506. 1991 Transplant. Proc. pmid:1721411
Shinozuka N et al. Correlation between simplified immunocompetence assay and clinical graft states in kidney or liver transplant recipients. 1996 Transplant. Proc. pmid:8658649
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Ju MK et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? 2008 Transplant. Proc. pmid:19100463
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
Wen J et al. Tripterygium wilfordii hook f increase the blood concentration of tacrolimus. 2008 Transplant. Proc. pmid:19100464
Baran DA et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. 2002 Transplant. Proc. pmid:12176609
van Gelder T et al. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. 2001 Transplant. Proc. pmid:11377580
Fieguth HG et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. 2002 Transplant. Proc. pmid:12176613
Kauffman HM et al. Drug regimens affect cadaveric kidney graft survival. 2001 Feb-Mar Transplant. Proc. pmid:11267176
Dudley CR Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267179
Navaneethan SD et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. 2006 Transplant. Proc. pmid:16797291
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
Chu Z et al. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients. 2010 Transplant. Proc. pmid:20832552
Hasegawa S et al. FK 506 and cyclosporine: effects and side effects in canine lung transplantation. 1991 Transplant. Proc. pmid:1721443
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
Thiru S et al. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. 1987 Transplant. Proc. pmid:2445086
Morales J et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. 2008 Transplant. Proc. pmid:19010240
Wang CH et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. 2004 Transplant. Proc. pmid:15561257
Aidong W et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. 2004 Transplant. Proc. pmid:15561258
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Escartín A et al. Orthotopic small bowel transplantation in pigs without steroids. 1999 Transplant. Proc. pmid:10500720
Ribas Y et al. Lack of accommodation after long-term survival of hamster xenografts in rats. 1999 Transplant. Proc. pmid:10500752
Hutchinson IV et al. Differences in the mode of action of cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636388
Müller V et al. Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney. 1998 Transplant. Proc. pmid:9636396
Granot E et al. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation. 2000 Transplant. Proc. pmid:10856551
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503